Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Bissera Pilicheva
 -- 2200 2022-08-18 16:00:00 |
2 Reference format revised.
Lindsay Dong
 Meta information modification 2200 2022-08-22 03:50:35 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Boyuklieva, R.;  Pilicheva, B. Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery. Encyclopedia. Available online: https://encyclopedia.pub/entry/26285 (accessed on 17 November 2024).
Boyuklieva R,  Pilicheva B. Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery. Encyclopedia. Available at: https://encyclopedia.pub/entry/26285. Accessed November 17, 2024.
Boyuklieva, Radka, Bissera Pilicheva. "Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery" Encyclopedia, https://encyclopedia.pub/entry/26285 (accessed November 17, 2024).
Boyuklieva, R., & Pilicheva, B. (2022, August 18). Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery. In Encyclopedia. https://encyclopedia.pub/entry/26285
Boyuklieva, Radka and Bissera Pilicheva. "Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery." Encyclopedia. Web. 18 August, 2022.
Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery
Edit
This entry is adapted from the peer-reviewed paper 10.3390/biomedicines10071706
The intranasal route of drug administration offers numerous advantages, such as bypassing the intestine, avoiding first-pass metabolism, and reducing systemic side effects. Moreover, it circumvents the BBB, providing direct entrance to the brain through the olfactory and trigeminal nerve pathways.  Micro- and nanotechnological approaches were widely used to overcome these limitations and enhance the availability of drugs in the brain tissue. Micro- and nanoparticulate carriers are composed of natural or synthetic materials that interact with biological structures at the molecular level and lead the treatment of NDs into a new direction. They may induce interaction between target sites, thus minimizing the side effects.
microparticles nanoparticles neurodegenerative disorders Alzheimer’s disease Parkinson’s disease nose-to-brain

1. The Nasal Route—A Shortcut to Deliver Therapeutics Directly to the Brain

The brain is undoubtedly the most protected organ in the human body from the entry of exogenous substances such as toxins and drug molecules. This protection is provided by different cells at three interfaces: the blood–brain barrier (BBB), the blood–cerebrospinal fluid barrier (BSB), and the arachnoid barrier [1]. To reach the brain, drug molecules must meet certain criteria: they should be non-ionized and lipophilic, with a molecular weight below 400 Da and capable of forming fewer than eight hydrogen bonds [2]. Most drugs used for the treatment of neurodegenerative disorders do not comply with the listed requirements for effective brain delivery. This has led scientists to search for alternative administration routes to bypass the BBB and harness the therapeutic potential of drug molecules. Therapeutics might be administered directly to the central nervous system (CNS) by intrathecal, intraparenchymal, and intracerebroventricular injections/infusions, but these routes are invasive and are not suitable for chronically administered drugs [3][4]. The nasal route has gained attention in recent years as non-invasive and easy-to-self-administer path that allows for rapid absorption and avoids the first-pass metabolism of therapeutics. The number of approved intranasal formulations is constantly growing, e.g., Rivamist® (rivastigmine intranasal spray) (Lachesis Biosciences Ltd, Warrnambool, Australia), and can be used to treat agitation associated with Alzheimer’s disease.
Nasal formulations have the potential for self-medication and good patient compliance. The human nasal cavity extends from the nostrils to the nasopharynx (12–14 cm in length) and contains four different types of epithelia and underneath mucosa: squamous, respiratory, transitional, and olfactory [5][6]. Nasally administered drugs are deposited in the respiratory or olfactory epithelium [7][8]. From the respiratory epithelium, drugs can be absorbed in the systemic circulation, and then can reach the CNS if they can cross the BBB. Regarding nose-to-brain delivery, olfactory mucosa, and the trigeminal nerve, which innervates the olfactory and respiratory mucosa, are of particular interest (Figure 1). The nasal route provides two pathways—intracellular and extracellular—that are responsible for the drug being transported directly to the brain [6]. The intracellular pathway involves endocytosis by sensory olfactory cells, axonal transport to their synaptic clefts, and exocytosis into the olfactory bulb, where neurons projecting to brain regions repeat the process [9]. The extracellular pathway directly transports drug molecules into the cerebrospinal fluid (CSF) through the paracellular space of the nasal epithelium and then through the perineural space to the subarachnoid space of the brain [9]. Both mechanisms contribute to the transportation of drug molecules, but the intracellular pathway is quite slow and cannot demonstrate the delivery of intranasal markers to all regions of the brain far beyond the projections of the olfactory bulb. Although reinforced by limited kinetic evidence, the extracellular pathway appears to be the main component of drug transport and should be the primary target [9]. It is reasonable that a combination of these pathways may occur (Figure 2), depending on the physicochemical properties of the drugs, characteristics of the formulation, and the type of drug-delivery device. The target region for nose-to-brain delivery is the olfactory epithelium in the upper nasal cavity. Due to the rich vascularization, the nasal mucosa generally serve as an effective absorption surface for therapeutic agents. However, the olfactory region, due to its proximity to the CSF, presents a direct connection to the CNS (nose-to-brain) [10].
/media/item_content/202208/6302df5f61939biomedicines-10-01706-g001.png
Figure 1. Nose-to-brain drug delivery. Schematic representation of olfactory and trigeminal neurons’ position in the nasal cavity; in purple-olfactory pathway, in green-trigeminal pathway. Created with BioRender.com (accessed on 25 June 2022).
/media/item_content/202208/6302df6b376c9biomedicines-10-01706-g002.png
Figure 2. Nose-to-brain drug-transport pathways. After nasal administration drug molecules can reach the brain via olfactory, systemic, and trigeminal pathways. Olfactory and trigeminal pathways avoid first-pass metabolism of drugs and bypass BBB to deliver molecules directly to the brain via transcellular and paracellular transport. Created with BioRender.com (accessed on 25 June 2022).

2. APIs Suited for Nose-to-Brain Drug Delivery

Dosage forms with targeted nose-to-brain delivery include mainly drugs that do not reach therapeutic concentrations in the brain tissue, otherwise administered, e.g., orally, drugs with a pronounced first-pass effect, and drugs with many peripheral side effects [11]. The main properties that affect the rate and extent to which drug molecules will be transported from the nasal cavity to the brain tissue are the molecular weight, lipophilicity, and the degree of dissociation [6].
Dopamine itself, for example, cannot be used for the treatment of Parkinson’s disease because it is incapable of crossing the BBB. In an animal study, dopamine levels were investigated in blood and cerebrospinal fluid to find out whether the drug was transferred along the olfactory pathway to the CNS following nasal administration. The drug was given intravenously or nasally. Higher dopamine levels in the brain were registered 30 min after nasal administration compared to those after intravenous administration. These results indicate that unchanged dopamine is transferred into the olfactory bulb via the olfactory pathway in rats [12]. Studies in humans have demonstrated that peptides such as melanocortin, vasopressin, and insulin, which have been shown to affect brain functions, including learning, memory, and cognition, accumulate in the brain tissue after intranasal administration [13]. Intranasal insulin was found to improve cognitive functions in patients with Alzheimer’s disease with no increase in peripheral blood levels [14].

3. Micro- and Nanoparticles for Nose-to-Brain Delivery

Various dosage forms (solutions [13][14], suspensions [15], microemulsions [16][17], gels [18]) have been prepared for nose-to-brain delivery. Conventional forms usually do not provide a controlled release of drug molecules and are not capable of targeted delivery [19]. There is usually a rapid release and absorption of the active molecules soon after administration, and a sharp increase in plasma concentration, which can lead to toxic effects. After a relatively short period of time, this concentration falls below therapeutic levels, and this may lead to more frequent use of the dosage form [19]. Particulate formulations can offer advantages over conventional forms, such as greater stability, convenience [20] and a long residence time in the nasal cavity [21]. Another important aspect to consider when looking at nose-to-brain drug delivery is to ensure that the formulation is deposited in the olfactory region, which can be achieved with the help of appropriate devices for both liquid and solid systems [22]. Furthermore, the nasal dosage form should be designed to provide an extended residence time and maintain a high local concentration for drug diffusion [23]. Particle size is another important feature in the development of an optimized delivery system for nose-to-brain administration. Nanoparticles, for example, permeate phospholipid membranes more easily than microparticles due to their smaller size, since the tight junctions of the nasal epithelium are smaller than 15 nm. Larger particles cannot permeate the epithelium; they release the drug in the mucosal tissue, where it is usually absorbed by passive diffusion. The surface charge of the carrier plays a crucial role in prolonging the contact time between the carrier and the mucosa. Microparticles with a positive charge may adhere to the mucosa due to the net-negative charge of the mucin.

4. Microparticles

Microparticles are drug-delivery systems, in the 1–1000 µm size range. They have both therapeutic and technological advantages based on their structural and functional abilities, such as modified and targeted drug delivery and release, protection of the encapsulated active agent against degradation, protection of the body from systemic side effects, dose titration and less dose dumping, more homogeneous distribution, and more predictable pharmacokinetics with reduced variables [24][25][26]. Microparticles can be considered as homogeneous or heterogeneous systems depending on the formulation and preparation process [27]. They can be incorporated in different dosage forms—liquids (solutions, emulsions, suspensions), semisolids (gels, creams, pastes), and solids (powders, granules, tablets) [25].
The deposition of particles in the human nasal cavity depends on the geometry of the nasal cavity on the one hand, and on the particles’ properties, such as size, shape, and density, on the other. Evidence in the literature suggests that particles larger than 20 µm show a preferential deposition in the anterior part of the nasal cavity on inhalation due to high inertial impaction [28], while particles smaller than 5 µm follow the airways and exit the nasal cavity [28]. Research data suggest that particles of around 10 µm in size may show a preferential deposition in the olfactory region when intranasally administered at normal inhalation rates [29]. This suggests that tailoring the carrier drug particle size (into micron-sized particles) can be a potential strategy to enhance the preferential deposition of drug particles in the olfactory region of the nasal cavity (Table 1). Since the mucoadhesive capacity is crucial for the increased residence time of drug-loaded particles in the nasal cavity, a common approach to prolonged deposition on the olfactory epithelium has been to use mucoadhesive polymers for the formulation of drug carriers [30].
Table 1. Polymeric and lipid microparticles developed for nose-to-brain delivery in the treatment of NDs.
Active Ingredient Polymer/Lipid Preparation Method Ref.
Polymeric microparticles
β-cyclodextrin,
Hydroxypropyl-β-cyclodextrin		 Chitosan, Alginate Spray-drying [31]
Deferoxamine mesylate Chitosan,
Methyl-β-cyclodextrin		 Spray-drying,
Freeze-drying		 [32]
Ropinirole Alginate, Chitosan Spray-drying [33]
Ropinirole Carbopol 974P, Guar gum Solvent evaporation [34]
Quercetin Methyl-β-cyclodextrin,
Hydroxypropyl-β-cyclodextrin		 Freeze-drying [35]
Rivastigmine Ethylcellulose, Chitosan Emulsion solvent evaporation [36]
FITC-dextrans Tamarind seed polysaccharide Spray-drying [37]
Lipid microparticles
Resveratrol Tristearin, Glyceryl behenate, Stearic acid Melt oil/water
emulsification		 [38]

5. Nanoparticles

The great interest in nanoparticles as drug delivery systems is due to numerous advantages such as targeted delivery of drug molecules, greater bioavailability, reduced risk of side effects, etc. [39]. Nanoparticles can incorporate both hydrophilic and hydrophobic drugs and can be used for a variety of administration routes. Inside the nasal cavity, particulates can undertake different pathways according to their size. If the size ranges between 10 and 300 nm, nanoparticles can deliver therapeutic agents through the olfactory pathway directly to the brain, if the size is less than 200 nm, the delivery will occur through clathrin-dependent endocytosis, and if it is in the range from 100 to 200 nm, the transport will occur by caveolae-mediated endocytosis [40]. Certainly, the particle size of the nanocarriers will play a crucial role in achieving brain targeting via the nasal route. However, many other factors, such as carrier type, drug properties, mucoadhesion and swelling capacity, would also be of great importance (Table 2).

Table 2. Polymeric and lipid nanoparticles developed for nose-to-brain delivery in the treatment of NDs.
Active Ingredient Polymer/Lipid Preparation Method Ref.
Polymeric nanoparticles
Bromocriptine Chitosan Ionic gelation [41]
Ropinirole Chitosan Ionic gelation [42]
Rivastigmine Chitosan Ionic gelation [43]
Galantamine Poly (lactic acid),
Poly (lactide-co-glycolide)		 Double emulsification
of solid-oil-water (s/o/w)		 [44]
Huperzine A Poly (lactide-co-glycolide) Emulsion
solvent evaporation		 [45]
Genistein Chitosan Ionic gelation [46]
Lipid nanoparticles
Paenol Soyabean lecithin High temperature emulsification/
low-temperature curing		 [47]
BACE1 (siRNA) Solid triglycerides Emulsion solvent evaporation [48]
Dopamine Gelucire® 50/13 Melt emulsification [49]
Pueraria flavones Borneol, stearic acid Emulsion solvent evaporation [50]
Pioglitazone Tripalmitin, MCM,
Stearyl amine		 Microemulsification [51]

6. Composites

Polymer nanocomposites (PNCs) are a new class of reinforced materials that are formed by the dispersion of nanoscale particles throughout a polymer matrix. Nanocomposites consist of a polymer matrix embedded with nanoparticles to improve a particular property of the material [52]. Researchers span the range from the synthesis of basic structures (such as micro- and nanoparticles functionalized with molecules, simple biomolecules, or polymers) to more complex structures. The main approach initially focused on the control of shape, size, and surface charges, and then on modulating the topology of their chemical composition. At present, many biocompatible and biodegradable polymers have been experimentally and/or clinically investigated for the preparation of polymer-based composites as drug carriers [53]. By designing a composite structure, specific physicochemical and mechanical properties may be obtained. The resulting material may show a combination of its components’ best properties, as well as interesting features that single constituents often do not possess [54]. Examples of polymer micro- and nanoparticulate carriers’ applications for drug delivery in Alzheimer’s and Parkinson’s disease models are quite numerous, and they can take advantage of a relatively large number of materials that are biodegradable and suitable for particulate synthesis, including polylactide-co-glycolide (PLGA), polylactic acid (PLA), chitosan (CS), gelatin, polycaprolactone, and polyalkyl cyanoacrylates [55]. Polymeric composites might help to ameliorate the quantity and kinetic release profile of potential and existing Alzheimer’s and Parkinson’s disease drugs. The composite structure should be able, after intranasal application, to stably adhere to outer nasal olfactory epithelium to promote the release of nanoparticles loaded with active molecules. Nanoparticles should then be able to cross the epithelium and migrate to the nervous cells that comprise the olfactory nerve and project to the olfactory bulbs [5][6][7][8]. It is worth noting that the polymeric composite, after residing for a sufficient time to release its nanoparticles, should be degraded and eliminated without discomfort for the patient [56]. At present, composite structures seem to be promising drug-carriers, with numerous advantages over conventional forms, but scholars still need to deepen our knowledge of their properties and the peculiar features that the resulting nanocomposites are able to gain upon their carefully arranged mixture.

References

  1. Kadry, H.; Noorani, B.; Cucullo, L. A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 2020, 17, 69.
  2. Pardridge, W.M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 2012, 32, 1959–1972.
  3. Belur, L.R.; Romero, M.; Lee, J.; Podetz-Pedersen, K.M.; Nan, Z.; Riedl, M.S.; Vulchanova, L.; Kitto, K.F.; Fairbanks, C.A.; Kozarsky, K.F.; et al. Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I. Front. Mol. Neurosci. 2021, 14, 618360.
  4. Yi, X.; Manickam, D.S.; Brynskikh, A.; Kabanov, A.V. Agile delivery of protein therapeutics to CNS. J. Control Release 2014, 190, 637–663.
  5. Gizurarson, S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr. Drug Deliv. 2012, 9, 566–582.
  6. Gänger, S.; Schindowski, K. Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa. Pharmaceutics 2018, 10, 116.
  7. Yarragudi, S.B.; Kumar, H.; Jain, R.; Tawhai, M.; Rizwan, S. Olfactory Targeting of Microparticles Through Inhalation and Bi-directional Airflow: Effect of Particle Size and Nasal Anatomy. J. Aerosol. Med. Pulm. Drug Deliv. 2020, 33, 258–270.
  8. Erdő, F.; Bors, L.A.; Farkas, D.; Bajza, Á.; Gizurarson, S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull. 2018, 143, 155–170.
  9. Crowe, T.P.; Greenlee, M.H.W.; Kanthasamy, A.G.; Hsu, W.H. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018, 195, 44–52.
  10. Crowe, T.P.; Hsu, W.H. Evaluation of Recent Intranasal Drug Delivery Systems to the Central Nervous System. Pharmaceutics 2022, 14, 629.
  11. Fortuna, A.; Alves, G.; Serralheiro, A.; Sousa, J.; Falcão, A. Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules. Eur. J. Pharm. Biopharm. 2014, 88, 8–27.
  12. Dahlin, M.; Jansson, B.; Björk, E. Levels of dopamine in blood and brain following nasal administration to rats. Eur. J. Pharm. Sci. 2001, 14, 75–80.
  13. Born, J.; Lange, T.; Kern, W.; McGregor, G.P.; Bickel, U.; Fehm, H.L. Sniffing neuropeptides: A transnasal approach to the human brain. Nat. Neurosci. 2002, 5, 514–516.
  14. Craft, S.; Baker, L.D.; Montine, T.J.; Minoshima, S.; Watson, G.S.; Claxton, A.; Arbuckle, M.; Callaghan, M.; Tsai, E.; Plymate, S.R.; et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch. Neurol. 2012, 69, 29–38.
  15. Patel, H.; Chaudhari, P.; Gandhi, P.; Desai, B.; Desai, D.; Dedhiya, P.; Vyas, B.; Maulvi, F. Nose to brain delivery of tailored clozapine nanosuspension stabilized using (+)-alpha-tocopherol polyethylene glycol 1000 succinate: Optimization and in vivo pharmacokinetic studies. Int. J. Pharm. 2021, 600, 120474.
  16. Vyas, T.K.; Babbar, A.K.; Sharma, R.K.; Singh, S.; Misra, A. Intranasal Mucoadhesive Microemulsions of Clonazepam: Preliminary Studies on Brain Targeting. J. Pharm. Sci. 2006, 95, 570–580.
  17. Vyas, T.K.; Babbar, A.K.; Sharma, R.K.; Singh, S.; Misra, A. Preliminary Brain-targeting Studies on Intranasal Mucoadhesive Microemulsions of Sumatriptan. AAPS PharmSciTech 2006, 7, E49–E57.
  18. Jayachandra Babu, R.; Dayal, P.; Pawar, K.; Singh, M. Nose-to-brain transport of melatonin from polymer gel suspensions: A microdialysis study in rats. J. Drug Target 2011, 19, 731–740.
  19. Maiti, S.; Sen, K.K. Introductory Chapter: Drug Delivery Concepts. In Advanced Technology for Delivering Therapeutics; Maiti, S.K., Sen, K.K., Eds.; IntechOpen: London, UK, 2017.
  20. Rassu, G.; Soddu, E.; Cossu, M.; Gavini, E.; Giunchedi, P.; Dalpiaz, A. Particulate formulations based on chitosan for nose-to-brain delivery of drugs. J. Drug Deliv. Sci. Technol. 2016, 32, 77–87.
  21. Dalpiaz, A.; Gavini, E.; Colombo, G.; Russo, P.; Bortolotti, F.; Ferraro, L.; Tanganelli, S.; Scatturin, A.; Menegatti, E.; Giunchedi, P. Brain uptake of an anti-ischemic agent by nasal administration of microparticles. J. Pharm. Sci. 2008, 97, 4889–4903.
  22. Warnken, Z.; Smyth, H.; Watts, A.; Weitman, S.; Kuhn, J.; Williams, R. Formulation and device design to increase nose to brain drug delivery. J. Drug Deliv. Sci. Technol. 2016, 35, 213–222.
  23. Djupesland, G.; Messina, J.; Mahmoud, R. The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview. Ther. Deliv. 2014, 5, 709–733.
  24. Yang, L.; Alexandridis, P. Physicochemical aspects of drug delivery and release from polymer-based colloids. Curr. Opin. Colloid Interface Sci. 2000, 5, 132–143.
  25. Lengyel, M.; Kállai-Szabó, N.; Antal, V.; Laki, A.J.; Antal, I. Microparticles, Microspheres, and Microcapsules for Advanced Drug Delivery. Sci. Pharm. 2019, 87, 20.
  26. Siepmann, J.; Siepmann, F. Microparticles Used as Drug Delivery Systems. In Smart Colloidal Materials; Richtering, W., Ed.; Springer: Berlin/Heidelberg, Germany, 2006; Volume 133, pp. 15–21.
  27. Coelho, J.; Ferreira, P.; Alves, P.; Cordeiro, R.; Fonseca, A.; Góis, J.; Gil, M. Drug delivery systems: Advanced technologies potentially applicable in personalized treatments. EPMA J. 2010, 1, 164–209.
  28. Maaz, A.; Blagbrough, I.S.; De Bank, P.A. In Vitro Evaluation of Nasal Aerosol Depositions: An Insight for Direct Nose to Brain Drug Delivery. Pharmaceutics 2021, 13, 1079.
  29. Cheng, Y.S. Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech 2014, 15, 630–640.
  30. Ugwoke, M.I.; Agu, R.U.; Verbeke, N.; Kinget, R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 2005, 57, 1640–1665.
  31. Gavini, E.; Rassu, G.; Haukvik, T.; Lanni, C.; Racchi, M.; Giunchedi, P. Mucoadhesive microspheres for nasal administration of cyclodextrins. J. Drug Target 2009, 17, 168–179.
  32. Rassu, G.; Soddu, E.; Cossu, M.; Brundu, A.; Cerri, G.; Marchetti, N.; Ferraro, L.; Regan, R.F.; Giunchedi, P.; Gavini, E.; et al. Solid microparticles based on chitosan or methyl-β-cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate. J. Control Release 2015, 201, 68–77.
  33. Hussein, N.; Omer, H.; Ismael, A.; Albed Alhnan, M.; Elhissi, A.; Ahmed, W. Spray-dried alginate microparticles for potential intranasal delivery of ropinirole hydrochloride: Development, characterization and histopathological evaluation. Pharm. Dev. Technol. 2020, 25, 290–299.
  34. Mantry, S.; Balaji, A. Formulation design and characterization of ropinirole hydrochoride microsphere for intranasal delivery. Asian J. Pharm. Clin. Res. 2017, 10, 195–203.
  35. Manta, K.; Papakyriakopoulou, P.; Chountoulesi, M.; Diamantis, D.; Spaneas, D.; Vakali, V.; Naziris, N.; Chatziathanasiadou, M.V.; Andreadelis, I.; Moschovou, K.; et al. Preparation and biophysical characterization of inclusion complexes with β-cyclodextrin derivatives for the preparation of possible nose-to-brain Quercetin delivery systems. Mol. Pharmaceut. 2020, 17, 4241–4255.
  36. Gao, Y.; Almalki, W.H.; Afzal, O.; Panda, S.K.; Kazmi, I.; Alrobaian, M.; Katouah, H.A.; Altamimi, A.S.A.; Al-Abbasi, F.A.; Alshehri, S.; et al. Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of Alzheimer’s disease. Biomed. Pharmacother. 2021, 141, 111829.
  37. Yarragudi, S.B.; Richter, R.; Lee, H.; Walker, G.F.; Clarkson, A.N.; Kumar, H.; Rizwan, S.B. Formulation of olfactory-targeted microparticles with tamarind seed polysaccharide to improve the transport of drugs. Carbohydr. Polym. 2017, 163, 216–226.
  38. Trotta, V.; Pavan, B.; Ferraro, L.; Beggiato, S.; Traini, D.; Des Reis, L.G.; Scalia, S.; Dalpiaz, A. Brain targeting of resveratrol by nasal administration of chitosan-coated lipid microparticles. Eur. J. Pharm. Biopharm. 2018, 127, 250–259.
  39. Ong, W.-Y.; Shalini, S.-M.; Constantino, L. Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders. Curr. Med. Chem. 2014, 21, 4247–4256.
  40. Khan, A.R.; Liu, M.; Khan, M.W.; Zhai, G. Progress in brain targeting drug delivery system by nasal route. J. Control Release. 2017, 268, 364–389.
  41. Md, S.; Khan, R.A.; Mustafa, G.; Chuttani, K.; Baboota, S.; Sahni, J.K.; Ali, J. Bromocriptine-loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, pharmacokinetic and scintigraphy study in mouse model. Eur. J. Pharm. Sci. 2013, 48, 393–405.
  42. Jafarieh, O.; Md, S.; Ali, M.; Baboota, S.; Sahni, J.K.; Kumari, B.; Bhatnagar, A.; Ali, J. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting. Drug Dev. Ind. Pharm. 2015, 41, 1674–1681.
  43. Fazil, M.; Md, S.; Haque, S.; Kumar, M.; Baboota, S.; Sahni, J.K.; Ali, J. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 2012, 47, 6–15.
  44. Nanaki, S.G.; Spyrou, K.; Bekiari, C.; Veneti, P.; Baroud, T.N.; Karouta, N.; Grivas, I.; Papadopoulos, G.C.; Gournis, D.; Bikiaris, D.N. Hierarchical Porous Carbon—PLLA and PLGA Hybrid Nanoparticles for Intranasal Delivery of Galantamine for Alzheimer’s Disease Therapy. Pharmaceutics 2020, 12, 227.
  45. Meng, Q.; Wang, A.; Hua, H.; Jiang, Y.; Wang, Y.; Mu, H.; Wu, Z.; Sun, K. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease. Int. J. Nanomed. 2018, 13, 705–718.
  46. Rassu, G.; Porcu, E.P.; Fancello, S.; Obinu, A.; Senes, N.; Galleri, G.; Migheli, R.; Gavini, E.; Giunchedi, P. Intranasal delivery of genistein-loaded nanoparticles as a potential preventive system against neurodegenerative disorders. Pharmaceutics 2019, 11, 8.
  47. Sun, Y.; Li, L.; Xie, H.; Wang, Y.; Gao, S.; Zhang, L.; Bo, F.; Yang, S.; Feng, A. Primary Studies on Construction and Evaluation of Ion-Sensitive in situ Gel Loaded with Paeonol-Solid Lipid Nanoparticles for Intranasal Drug Delivery. Int. J. Nanomed. 2020, 15, 3137–3160.
  48. Rassu, G.; Soddu, E.; Posadino, A.M.; Pintus, G.; Sarmento, B.; Giunchedi, P.; Gavini, E. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy. Colloids Surf. B Biointerfaces 2017, 152, 296–301.
  49. Cometa, S.; Bonifacio, M.A.; Trapani, G.; Di Gioia, S.; Dazzi, L.; De Giglio, E.; Trapani, A. In vitro investigations on dopamine loaded Solid Lipid Nanoparticles. J. Pharm. Biomed. Anal. 2020, 185, 113257.
  50. Wang, L.; Zhao, X.; Du, J.; Liu, M.; Feng, J.; Hu, K. Improved brain delivery of pueraria flavones via intranasal administration of borneol-modified solid lipid nanoparticles. Nanomedicine 2019, 14, 2105–2119.
  51. Jojo, G.; Kuppusamy, G.; De, A.; Karri, V. Formulation and optimization of pioglitazone intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer’s disease using Box-Behnken design. Drug Dev. Ind. Pharm. 2019, 45, 1061–1072.
  52. Omanović-Mikličanin, E.; Badnjević, A.; Kazlagić, A.; Hajlovac, M. Nanocomposites: A brief review. Health Technol. 2020, 10, 51–59.
  53. Liechty, W.B.; Kryscio, D.R.; Slaughter, B.V.; Peppas, N.A. Polymers for drug delivery systems. Ann. Rev. Chem. Biomol. Eng. 2010, 1, 149–173.
  54. Nicolais, L.; Gloria, A.; Ambrosio, L. The mechanics of biocomposites. In Biomedical Composites, 1st ed.; Ambrosio, L., Ed.; CRC Press: London, UK, 2010; pp. 411–440.
  55. Jiang, L.; Gao, L.; Wang, X.; Tang, L.; Ma, J. The application of mucoadhesive polymers in nasal drug delivery. Drug Dev. Ind. Pharm. 2010, 36, 323–336.
  56. Suh, W.H.; Suslick, K.S.; Stucky, G.D.; Suh, Y.H. Nanotechnology, nanotoxicology, and neuroscience. Prog. Neurobiol. 2009, 87, 133–170.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Pharmacology & Pharmacy
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Radka Boyuklieva
,
Bissera Pilicheva
View Times: 742
Entry Collection: Neurodegeneration
Revisions: 2 times (View History)
Update Date: 22 Aug 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback